Get the Stockscreener App
11.35
3.75%
0.41
Gyre Therapeutics Inc stock is traded at $11.35, with a volume of 140.70K.
It is up +3.75% in the last 24 hours and up +42.95% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$10.94
Open:
$10.99
24h Volume:
140.70K
Relative Volume:
0.94
Market Cap:
$999.94M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
121.39
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+19.10%
1M Performance:
+42.95%
6M Performance:
-13.49%
1Y Performance:
-25.77%
1-Day Range:
$10.99
$11.67
1-Week Range:
$9.47
$11.78
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
11.35 | 839.60M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Barclays PLC - Defense World
Gyre Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Has $49,000 Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
GYRE Makes Bullish Cross Above Critical Moving Average - Nasdaq
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s Why - Defense World
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports Q1 2025 Revenue of $22.1 Million and Progress in Clinical Development and Commercialization Efforts - Nasdaq
Earnings Flash (GYRE) Gyre Therapeutics Reports Q1 Revenue $22.1M, vs. FactSet Est of $28.4M - marketscreener.com
Taking A Look At Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE - simplywall.st
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity - Yahoo Finance
Gyre Therapeutics Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView
GNI Group Confirms NDA Timeline for Hydronidone - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GYRE Stock Plummets to 52-Week Low at $6.15 Amid Market Challenges - Investing.com Canada
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga
GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges - Investing.com UK
Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury - MarketScreener
Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks
Major Breakthrough: Gyre's Cancer Drug Trial Targets 25% of Radiation Therapy Patients - Stock Titan
Bank of New York Mellon Corp Has $168,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Yahoo Finance
Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment - Stock Titan
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 - Investing.com Australia
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% – Here’s Why - Defense World
Gyre therapeutics president Ma Songjiang sells $40,440 in stock By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells $40,440 in stock - Investing.com India
GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha
Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings - TipRanks
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock - Investing.com
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Gyre Therapeutics Inc (GYRE) Q4 2024 Earnings: Revenue Surpasses Estimates at $27.9M, EPS Misses at $0.00 - GuruFocus.com
Impact of New U.S. Regulations on Gyre Therapeutics: Potential Delisting Risks and Investor Concerns - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings - Defense World
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Gyre Therapeutics (GYRE) Projected to Post Earnings on Tuesday - Defense World
Decoding Gyre Therapeutics Inc (GYRE): A Strategic SWOT Insight - GuruFocus
Gyre Therapeutics offers weak 2025 revenue guidance - Investing.com India
Gyre Therapeutics offers weak 2025 revenue guidance By Investing.com - Investing.com Canada
Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases -March 17, 2025 at 04:52 pm EDT - Marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
(GYRE) Gyre Therapeutics Sees 2025 Revenue Range $118M$128M -March 17, 2025 at 04:18 pm EDT - Marketscreener.com
FY2024 Earnings Forecast for GYRE Issued By Noble Financial - Defense World
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock By Investing.com - Investing.com Canada
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock - Investing.com India
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
| Ma Songjiang | President |
May 13 '25 |
Sale |
11.37 |
2,000 |
22,740 |
2,820,844 |
| Ma Songjiang | President |
May 12 '25 |
Sale |
10.56 |
2,000 |
21,120 |
2,822,844 |
| Ye Weiguo | Chief Operating Officer |
Mar 24 '25 |
Option Exercise |
0.75 |
300,000 |
225,000 |
300,000 |
| Ye Weiguo | Chief Operating Officer |
Mar 26 '25 |
Option Exercise |
0.75 |
200,000 |
150,000 |
500,000 |
| Ye Weiguo | Chief Operating Officer |
Mar 27 '25 |
Option Exercise |
0.75 |
150,000 |
112,500 |
650,000 |
| Eastling Thomas Wilson | Director |
Apr 16 '25 |
Option Exercise |
6.93 |
15,000 |
103,950 |
15,000 |
| Ma Songjiang | President |
Mar 21 '25 |
Sale |
10.00 |
174 |
1,740 |
2,824,844 |
| Ma Songjiang | President |
Mar 19 '25 |
Sale |
10.13 |
2,000 |
20,260 |
2,827,018 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):